CEO: Phillip Gomez, Ph.D
HQ: New York, NY
SIGA is a leader in providing solutions for unmet needs in the estimated $10 billion global health security market. In 2018, the U.S. Food and Drug Administration approved SIGA’s first product, oral TPOXX® (tecovirimat), for the treatment of smallpox, a deadly bioterrorism threat that cannot be addressed through vaccines alone. SIGA has worked closely with the U.S. Government during the development of TPOXX® and has been awarded more than $1.1 billion in procurement and development contracts by the Biomedical Advanced Research and Development Authority of the U.S. Government (BARDA). Most recently, SIGA was awarded in a BARDA contract in excess of $600 million for the maintenance of 1.7 million courses of smallpox antiviral in the strategic national stockpile. SIGA is developing an intravenous formulation of TPOXX and pursuing product and market expansion opportunities including a pediatric formulation, post-exposure prophylaxis indication, and international sales.